Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PanAd3-RSV
- Development stage
- Phase 1
- Lead developer
- ReiThera
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
PanAd3-RSV is a replication-defective chimpanzee adenovirus-vectored vaccine candidate developed for the prevention of respiratory syncytial virus (RSV) infection. The vaccine uses a genetically modified adenoviral vector (PanAd3, derived from chimpanzee adenovirus group C) to deliver codon-optimized genes encoding RSV proteins F (fusion protein, F0ΔTM), N (nucleocapsid protein), and M2–1 (matrix protein). This design aims to induce both humoral and cellular immune responses against RSV. Clinical studies have shown that PanAd3-RSV is safe and immunogenic in healthy adults, including older adults, with balanced CD4+ and CD8+ T cell responses as well as neutralizing antibody production. The vaccine has been evaluated alone or in combination with MVA-RSV in prime-boost regimens[2][5][6].
02
Targets
M2-1 (Respiratory syncytial virus transcription antitermination factor M2-1)RSV F (Respiratory syncytial virus fusion protein)RSV N (Respiratory syncytial virus nucleoprotein)
Beyond the preview
Go deeper on PanAd3-RSV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PanAd3-RSV.